

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* <b>Bonita David P</b>			2. Issuer Name and Ticker or Trading Symbol <b>Ikena Oncology, Inc. [ IKNA ]</b>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) <b>03/30/2021</b>					
601 LEXINGTON AVENUE 54TH FLOOR			4. If Amendment, Date of Original Filed (Month/Day/Year) <b>04/01/2021</b>			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person		
(Street)								
NEW YORK NY 10022								
(City)	(State)	(Zip)						

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	03/30/2021		C		1,470,872	A	(1)	1,470,872	I	See footnotes <sup>(2)(8)</sup>
Common Stock	03/30/2021		C		42,614	A	(1)	42,614	I	See footnotes <sup>(3)(8)</sup>
Common Stock	03/30/2021		P		375,000	A	\$16	1,845,872	I	See footnotes <sup>(2)(8)</sup>
Common Stock	03/30/2021		P		48,400	A	\$16	91,014	I	See footnotes <sup>(3)(8)</sup>
Non-Voting Common Stock	03/30/2021		C		5,429,023	A	(1)	5,429,023	I	See footnotes <sup>(2)(8)</sup>
Non-Voting Common Stock	03/30/2021		C		157,288	A	(1)	157,288	I	See footnotes <sup>(3)(8)</sup>

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series B Preferred Stock	(1)	12/21/2020		A <sup>(4)</sup>		8,938,148		(1)	(1)	Common Stock <sup>(5)</sup>	1,249,391 <sup>(5)</sup>	\$1.3985	8,938,148	I	See footnotes <sup>(2)(8)</sup>
Series B Preferred Stock	(1)	12/21/2020		A <sup>(4)</sup>		1,430,103		(1)	(1)	Common Stock <sup>(6)</sup>	199,902 <sup>(6)</sup>	\$1.3985	1,430,103	I	See footnotes <sup>(3)(8)</sup>
Series A Preferred Stock	(1)(7)	03/30/2021		C		2,034,708		(7)	(7)	Non-Voting Common Stock	2,034,708	(7)	0	I	See footnotes <sup>(2)(8)</sup>
Series A Preferred Stock	(1)	03/30/2021		C		551,259		(1)	(1)	Common Stock	551,259	(1)	0	I	See footnotes <sup>(2)(8)</sup>
Series A-1 Preferred Stock	(1)(7)	03/30/2021		C		2,411,260		(7)	(7)	Non-Voting Common Stock	2,411,260	(7)	0	I	See footnotes <sup>(2)(8)</sup>
Series A-1 Preferred Stock	(1)	03/30/2021		C		653,277		(1)	(1)	Common Stock	653,277	(1)	0	I	See footnotes <sup>(2)(8)</sup>
Series B Preferred Stock	(1)(7)	03/30/2021		C		983,054		(7)	(7)	Non-Voting Common Stock	983,054	(7)	0	I	See footnotes <sup>(2)(8)</sup>
Series B Preferred Stock	(1)	03/30/2021		C		266,337		(1)	(1)	Common Stock	266,337	(1)	0	I	See footnotes <sup>(2)(8)</sup>
Series B Preferred Stock	(1)(7)	03/30/2021		C		157,288		(7)	(7)	Non-Voting Common Stock	157,288	(7)	0	I	See footnotes <sup>(3)(8)</sup>
Series B Preferred Stock	(1)	03/30/2021		C		42,614		(1)	(1)	Common Stock	42,614	(1)	0	I	See footnotes <sup>(3)(8)</sup>

Explanation of Responses:

- Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock, and Series B Preferred Stock (together, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. These shares of Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date.
- The securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"), OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered

investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP VI. The Reporting Person is a member of OrbiMed Advisors. By virtue of such relationship, OrbiMed Advisors and GP VI may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI VI.

3. The securities are held of record by OrbiMed Genesis Master Fund, L.P. ("OrbiMed Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of OrbiMed Genesis. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationship, OrbiMed Advisors and Genesis GP may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OrbiMed Genesis.

4. This transaction occurred prior to the Issuer's initial public offering and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Persons' Form 3.

5. Represents 266,337 shares of Common Stock and 983,054 shares of Non-Voting Common Stock issuable upon conversion.

6. Represents 42,614 shares of Common Stock and 157,288 shares of Non-Voting Common Stock issuable upon conversion.

7. Each share of Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. These shares of Preferred Stock converted into Non-Voting Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. Each share of Non-Voting Common Stock is convertible into one share of Common Stock at any time at the option of the holder without payment or additional consideration, subject to a 9.9% beneficial ownership limitation which may be increased or decreased by the holder upon 61 days' notice to the Issuer.

8. Each of the GP VI, Genesis, OrbiMed Advisors, and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose. OrbiMed Advisors has designated the Reporting Person as its representative on the Issuer's Board of Directors.

#### Remarks:

This Form 4 amends and restates the Form 4 filed by the Reporting Person on April 1, 2021 to reflect the correct split between shares of Common Stock and Non-Voting Common Stock.

/s/ David P. Bonita

04/14/2021

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**